What is Definium Therapeutics, Inc. (DFTX)?

Definium Therapeutics, Inc. (DFTX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of DFTX?

The current price of DFTX is $36.33. Prices are updated in real time on Stocks360.

What is DFTX's price-to-earnings (PE) ratio?

DFTX's trailing twelve-month PE ratio is -10.56, based on current price and earnings per share data available on Stocks360.

What is DFTX's market capitalization?

DFTX's market capitalization is $4,881,550,930.00, placing it in the mid-cap tier.

Definium Therapeutics, Inc. (DFTX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$36.33

Market Cap

$4.88B

PE (TTM)

-10.56

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.19

Day Range

$35.87 – $37.90

52-wk Range

$12.88 – $49.20

Avg Volume

N/A

Volume

847.47K

Definium Therapeutics, Inc. (DFTX) is a publicly traded company in the Healthcare sector. Latest price: $36.33. Market cap $4.88B. Trailing PE -10.56. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $14.20 2026-10-30 · $36.33 (+155.85%)

Earnings

Most Recent

Aug 6, 2026

EPS $-1.44 vs est. $-0.54

Missed by $0.90

Next Earnings

Nov 9, 2026

EPS estimate $-0.56

Proprietary Signals

Signal snapshot temporarily unavailable.

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-10.56×
P/S (TTM)	0.00×
P/B	4.38×
PEG	0.14×
P/FCF (TTM)	-29.25×
EV / EBITDA	-12.55×
EV / Sales	0.00×
Earnings Yield	-8.80%
Free Cash Flow Yield	-3.42%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$4.26B
Net Income (TTM)	-$429.48M
Free Cash Flow (TTM)	-$153.42M
Net Debt	-$618.80M
Working Capital	$934.90M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-85.23%
Return on Invested Capital	-23.81%